Major bleeding · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · people with cancer with VTE receiving secondary prophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent venous thromboembolism (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Health‐related quality of life ‐ not reported · people with cancer with VTE receiving secondary prophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent venous thromboembolism · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).
1 finding from 1 review
Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Success of withdrawal from antipsychotics · older people with dementia who had been taking an antipsychotic drug for at least 3 months
Discontinuation may leads to lower success of withdrawal from antipsychotics compared with continuation of antipsychotic medication (low certainty).
1 finding from 1 review
Behavioural and psychological symptoms · older people with dementia who had been taking an antipsychotic drug for at least 3 months
1 finding from 1 review
Adverse events · older people with dementia who had been taking an antipsychotic drug for at least 3 months
1 finding from 1 review
QoL · older people with dementia who had been taking an antipsychotic drug for at least 3 months
1 finding from 1 review
Cognitive function · older people with dementia who had been taking an antipsychotic drug for at least 3 months
1 finding from 1 review
Use of physical restraints · older people with dementia who had been taking an antipsychotic drug for at least 3 months
1 finding from 1 review
All‐cause mortality · older people with dementia who had been taking an antipsychotic drug for at least 3 months
1 finding from 1 review
Mortality: in‐hospital mortality (time points varied) · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: in‐hospital mortality (time points varied) compared with standard practice storage duration (moderate certainty).
1 finding from 1 review
ICU mortality · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: in‐ICU mortality compared with standard practice storage duration (moderate certainty).
1 finding from 1 review
Mortality: short‐term mortality (up to 30 days) ‐ neonates · all conditions
It is very uncertain whether transfusion of RBCs of shorter changes mortality: short‐term mortality (up to 30 days) ‐ neonates compared with standard practice storage duration (very low certainty).
1 finding from 1 review